Detalhe da pesquisa
1.
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.
Nature
; 610(7930): 161-172, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171284
2.
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.
Blood
; 143(1): 57-63, 2024 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37824808
3.
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Blood
; 143(21): 2152-2165, 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437725
4.
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Blood
; 133(18): 1964-1976, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30850381
5.
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
J Immunol
; 200(7): 2304-2312, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29453281
6.
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.
Cancer Immunol Immunother
; 66(1): 129-140, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27858101
7.
Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Eur J Haematol
; 97(5): 461-470, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26993060
8.
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity.
J Immunol
; 192(5): 2252-60, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24489098
9.
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.
Med
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38593812
10.
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.
Haematologica
; 103(2): e78-e81, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079598
11.
Explainable machine learning for profiling the immunological synapse and functional characterization of therapeutic antibodies.
Nat Commun
; 14(1): 7888, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38036503
12.
Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation.
Elife
; 122023 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127790
13.
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies.
Clin Cancer Res
; 29(21): 4449-4463, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379429
14.
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Blood
; 115(22): 4393-402, 2010 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-20194898
15.
Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Arch Biochem Biophys
; 526(2): 206-18, 2012 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22464987
16.
A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis.
AAPS J
; 24(1): 7, 2021 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862519
17.
Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling.
Mol Cancer Ther
; 20(2): 357-366, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33298591
18.
FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies.
J Chromatogr A
; 1610: 460554, 2020 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31597603
19.
Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
J Pharmacol Exp Ther
; 329(1): 360-7, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19147858
20.
Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab.
Sci Rep
; 9(1): 13675, 2019 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31548565